Technical Analysis for NAVB - Navidea Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 3.2 12.28% 0.35
NAVB closed up 12.28 percent on Friday, June 5, 2020, on 63 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up
Historical NAVB trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
New 52 Week Closing High Bullish 12.28%
Wide Bands Range Expansion 12.28%
New 52 Week Closing High Bullish 19.85%
Wide Bands Range Expansion 19.85%
Wide Bands Range Expansion 22.14%
Wide Bands Range Expansion 22.14%
New 52 Week Closing High Bullish 22.14%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company's radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule investigational radiopharmaceutical that is used in lymphatic mapping procedures, which are performed to help stage breast cancer and melanoma; and NAV4694, an F-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer's disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; and RIGScan, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. It has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Medicine Biopharmaceutical Surgery Alzheimer's Disease Parkinson's Disease Medical Physics Melanoma Dementia Tomography Movement Disorders Metastasis Medicinal Radiochemistry Nuclear Medicine Radiopharmaceuticals University Of California Positron Emission Tomography Cognitive Impairment F 18 Positron Corporation Radiochemistry

Is NAVB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.5
52 Week Low 0.49
Average Volume 2,026,347
200-Day Moving Average 1.00
50-Day Moving Average 1.23
20-Day Moving Average 1.88
10-Day Moving Average 2.65
Average True Range 0.27
ADX 65.49
+DI 55.26
-DI 3.54
Chandelier Exit (Long, 3 ATRs ) 2.68
Chandelier Exit (Short, 3 ATRs ) 1.67
Upper Bollinger Band 3.48
Lower Bollinger Band 0.27
Percent B (%b) 0.91
BandWidth 170.72
MACD Line 0.53
MACD Signal Line 0.42
MACD Histogram 0.1109
Fundamentals Value
Market Cap 518.4 Million
Num Shares 162 Million
EPS 0.48
Price-to-Earnings (P/E) Ratio 6.67
Price-to-Sales 3.31
Price-to-Book 4.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.86
Resistance 3 (R3) 3.80 3.52 3.75
Resistance 2 (R2) 3.52 3.35 3.55 3.71
Resistance 1 (R1) 3.36 3.25 3.44 3.42 3.68
Pivot Point 3.08 3.08 3.12 3.11 3.08
Support 1 (S1) 2.92 2.91 3.00 2.98 2.72
Support 2 (S2) 2.64 2.81 2.67 2.69
Support 3 (S3) 2.48 2.64 2.65
Support 4 (S4) 2.54